ALBANY, New York, September 28, 2016: ResearchMoz.us now features a research report, titled “Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth.” The report serves as a repository of analysis and information regarding various aspects including classification, treatment options, segments, treatment algorithm, and prognosis for type 2 diabetes mellitus. The South-east Asia type 2 diabetes mellitus therapeutics (T2DM) market was valued at US$1.7 bn in 2015 and is expected to expand at a CAGR of 7.1% from 2015 to 2022, reaching a value of US$2.7 bn in 2022.

The report provides an in-depth analysis of clinical trial procedures and different products including different types of drugs, therapies, and treatment options. It presents a detailed evaluation of pipeline drugs including promising pipeline candidates. As per the findings of the report, there are over 500 active pipeline molecules and most of the late-stage investigational drugs being evaluated by scientists are exhibiting improved administration routes and dosing regimens as compared to existing products.

The key reason for the growth of the T2DM market in South-east Asia is the increasing prevalence of diabetes in the region. The increasing use of new therapies has paved way for clinical advancements in the field of type 2 diabetes mellitus therapeutics treatment. The rising uptake of recently approved drugs such as Victoza (a type of GLP-1 receptor agonist), Jardiance (an SGLT-2 inhibitor), and Januvia (a DPP-4 inhibitor) along with other emerging treatment options including thiazolidinediones, sulfonylureas, insulin therapies, and biguanide (metformin) is driving the market. Moreover, high unmet needs related to patient convenience are contributing to the growth of the market. Other factors fuelling the demand for T2DM are a rising geriatric population, improving economic conditions, and increasing awareness.

However, the availability of generic drugs at low costs is adversely affecting the overall revenue earnings of the market. The demand for the generic version of drugs is further encouraged by the patent expiration of blockbuster drugs. Therefore, the widespread usage of generic drugs is likely to hamper the growth of the South-east Asia T2DM market. Moreover, poor adherence to treatment regimens and non-pharmacological first-line treatment are likely to hinder the growth of the market. For instance, as per the analysis of clinical trials since 2006, the overall attrition rate for T2DM stood at 75%, with failure rates highest in phase III, accounting for 49% of the overall failures.

The report provides a holistic perspective of the market’s growth across key countries of the South-east Asia region such as South Korea, Singapore, Malaysia, Taiwan, Thailand, Philippines, Indonesia, and Vietnam in terms of revenue. It gives details about treatment usage patterns, annual cost of therapy, and market size of these countries. It offers insights into the deals and strategic consolidations of key players in the market.